Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Intranasal Methylprednisolone
NCT05649878Phase 1Completed
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methylprednisolone sodium succinate in inflammation. Primary endpoint: Absolute Bioavailability of Methylprednisolone at 24 hours. Started Nov 2021; status: completed.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT05649878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649878.